Oct 23, 2024
Gilead Sciences’ Covid-19 treatment to receive reimbursement
Gilead Sciences Korea said its Covid-19 treatment, Veklury (ingredient: remdesivir), will be covered under the national health insurance system starting from Oct. 25. Veklury is a direct-acting antiviral agent that inhibits viral RNA synthesis.
Read More
Oct 23, 2024
COVID-19 treatment Veklury to be covered from the 25th
Gilead Sciences Korea (CEO Jae-yeon Choi) announced that health insurance benefits for the COVID-19 treatment drug ‘Veklury (ingredient name: Remdesivir)’ will be applied from October 25 in accordance with the partial revision (draft) of the details on the application criteria and methods of the Ministry of Health and Welfare’s nursing care benefits.
Read More
Oct 22, 2024
Paxlovid effective for people with prior immunity, study shows
Paxlovid reduced the risk for severe COVID-19 hospitalization or death among people with existing immunity from a previous infection or vaccination, according to pooled trial data presented at IDWeek.
Read More